PEPTIDE SCIENCE EDUCATION
Stability & Formulation
Learn why peptide stability depends on the molecule, formulation, environment, packaging, and the evidence used to measure change.
A peptide does not have one universal "stability number."
Stability describes whether important quality attributes remain sufficiently controlled over time under defined conditions. The answer can change with the molecule, concentration, pH, excipients, physical state, manufacturing process, container, light exposure, temperature, moisture, and other factors.
That is why a storage or shelf-life claim from one product cannot automatically be transferred to another product simply because the active peptide has the same name.
Educational content only. Stability depends on the exact molecule, formulation, presentation, manufacturing process, container, and evidence package. Product-specific regulatory or manufacturer labeling applies only to the product it describes. This module does not provide preparation, reconstitution, administration, dosing, or MitoCore product-storage instructions.
What Stability Means
Stability is broader than whether a vial still looks normal.
Chemical stability asks whether the molecule is undergoing reactions such as oxidation, deamidation, or hydrolysis.
Physical stability asks whether the material is changing through processes such as aggregation, precipitation, adsorption, or other changes in physical state.
For some products, biological activity or potency is also an important part of the stability picture.
No single test answers every one of these questions.
Why Peptides Can Change
Peptides are chains of amino acids, and different sequences create different chemical weak points.
Oxidation can affect susceptible residues. Deamidation can occur at certain asparagine or glutamine sites. Hydrolysis can cleave susceptible bonds. Some peptides can self-associate or aggregate. Molecules containing disulfide bonds can have additional routes of structural change.
Which pathway matters most is molecule-specific. The same stress may have little effect on one peptide and a major effect on another.
View sources
- Peer-reviewedTorosantucci R, Schöneich C, Jiskoot W — Oxidation of Therapeutic Proteins and Peptides
- Peer-reviewedDesigning Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review
- Peer-reviewedFactors affecting the physical stability (aggregation) of peptide therapeutics
Oxidation
Some peptide residues are susceptible to oxidation. Whether oxidation is a meaningful stability risk depends on the molecule and the formulation.
Deamidation
A sequence-dependent chemical change that can alter a peptide over time. Its rate can change substantially with pH, temperature, and local sequence.
Hydrolysis
Can cleave susceptible chemical bonds. Stress studies commonly evaluate hydrolytic susceptibility across different pH conditions.
Aggregation
Not purely a storage-temperature issue. Can be influenced by the molecule, concentration, formulation, interfaces, impurities, and mechanical stress.
Interface / Adsorption
Some peptide and protein formulations are sensitive to interfaces and surfaces, which is one reason container and excipient choices can matter.
Disulfide-Related Change
Where applicable: for molecules that contain disulfide bonds, disulfide scrambling or exchange can be another route of structural change.
Why Formulation Matters
The active peptide is only one part of a finished formulation.
pH can change reaction rates, charge, solubility, and aggregation behavior. Buffers help control pH but can also influence molecular and interfacial behavior. Salts, sugars, polyols, surfactants, preservatives, and other excipients can change how a formulation responds to stress.
That does not mean every excipient is a stabilizer. An excipient that helps one formulation may be unnecessary or even unfavorable in another.
The container matters too. The material may interact with glass, polymers, stoppers, device components, air-water interfaces, or other surfaces. Packaging can also affect exposure to light, oxygen, or moisture.
View sources
- Peer-reviewedDesigning Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review
- Peer-reviewedManning MC et al. — Role of Buffers in Protein Formulations
- ICHICH Q1A(R2) — Stability Testing of New Drug Substances and Products, Step 4, 6 February 2003
- ICHFDA / ICH Q5C — Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, July 1996
Molecule
The peptide's own sequence and chemical weak points.
Formulation
pH, buffer, ionic conditions, excipients, and concentration.
Environment
Temperature, light, oxygen, moisture, and mechanical stress.
Packaging
Container, closure, and contact-surface interactions.
Time
Whether change is measured in a snapshot or across a defined period.
pH
One of the strongest formulation variables because it can change both chemical reaction rates and a molecule's physical behavior.
Buffer
Does more than hold a pH number. Buffer identity and concentration can also influence molecular and interfacial behavior.
Ionic Conditions
Can change how charged peptide molecules interact with each other and with their environment.
Excipients
Not automatically a stabilizer. Effect depends on the molecule, the formulation, and the stress being controlled.
Concentration
One of several factors -- alongside sequence, pH, charge, excipients, and interfaces -- that can influence aggregation and other stability behavior.
Container / Closure
Part of the formulation system. Contact surfaces, closure materials, light protection, and moisture transfer can all affect the stability evidence a finished product needs.
Environmental Stressors
Temperature, light, oxygen, moisture, and mechanical stress can all affect stability.
These factors do not have universal effects across all peptides. Stability testing is designed to determine which stresses matter for a specific drug substance or finished product and how quickly relevant quality attributes change.
View sources
- ICHICH Q1A(R2) — Stability Testing of New Drug Substances and Products, Step 4, 6 February 2003
- ICHFDA / ICH Q1B — Photostability Testing of New Drug Substances and Products, March 1996
- ICHFDA / ICH Q5C — Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, July 1996
Temperature
Can accelerate some degradation processes, but the effect is molecule- and formulation-specific.
Light
Can be a relevant stressor for some drug substances and products. Photostability is evaluated separately because sensitivity is product specific.
Oxygen
Relevant where a formulation is susceptible to oxidative degradation pathways.
Moisture
Residual moisture can increase molecular mobility and chemical reactivity in some dried systems, particularly for solid and lyophilized products.
Mechanical Stress
Agitation, shear, and interfacial stress are recognized environmental sensitivities for biological products and can contribute to aggregation.
Lyophilization
Lyophilization, or freeze-drying, removes water from a frozen material under reduced pressure.
At a high level, the process involves freezing, primary drying, and secondary drying. Removing most of the water can improve stability for some molecules that are less stable in solution.
But freeze-drying is not an automatic guarantee of stability. Freezing and drying create their own stresses, and the resulting solid can still change during storage. Residual moisture, formulation composition, temperature, and the physical state of the dried material can all matter.
A well-formed dry cake does not prove identity, purity, potency, sterility, or long-term stability.
View sources
Step 1
Freeze
The material is frozen as the first conceptual stage of the process.
Step 2
Primary Drying
Most of the water is removed under reduced pressure.
Step 3
Secondary Drying
Residual moisture is further reduced from the dried matrix.
Step 4
Dried Product
A solid material whose stability still depends on formulation, residual moisture, and storage conditions.
Dry does not mean indefinitely stable.
How Stability Is Measured
Stability is measured with methods chosen for the specific product.
Chromatographic methods such as HPLC or UPLC can track purity profiles, assay, and certain degradation products. Mass spectrometry can help characterize molecular mass and degradation products. Size-exclusion chromatography may be useful for aggregation or size variants where applicable. Some products also require methods that measure biological activity or potency.
The important idea is not the name of one instrument. It is whether the overall analytical program can detect meaningful change in the quality attributes that matter for that product.
Stress Testing vs Real-Time Stability
Stress studies deliberately challenge a drug substance or product to help identify degradation pathways and show whether analytical methods can detect change.
Accelerated studies can provide earlier information about stability behavior.
Real-time stability studies follow the product under defined storage conditions over time and are the primary basis for product-specific shelf-life or storage-period claims in formal stability programs.
A stress study is useful evidence, but it is not the same thing as a real-time shelf-life study.
View sources
Stress / Accelerated
Learn how a product can change.
Real-Time
Measure change under defined storage conditions.
COA vs Stability Study
A COA is a snapshot. A stability study is a time series.
A COA may show that selected quality attributes met specifications when a sample was tested. That does not automatically tell you how the material will change over months of storage, after exposure to heat or light, or in a different formulation.
A stability claim requires evidence designed to measure change over time.
View sources
COA
- A report of selected analytical results for a specific sample or lot.
- May include identity, purity, assay/content, sterility, endotoxin, residual moisture, or other attributes depending on the testing plan.
- Usually a point-in-time quality document.
Stability Study
- Evaluates change over time.
- Uses defined storage or stress conditions and stability-indicating methods.
- Supports storage conditions, retest periods, or shelf-life/expiration claims for the specific material or product.
Same Peptide, Different Product
FDA labeling for semaglutide shows why formulation specificity matters.
Ozempic is an aqueous injectable semaglutide formulation. Rybelsus is an oral semaglutide tablet with a very different excipient and presentation system. Their labeling therefore contains different formulation and storage/handling information.
The lesson is not that one formulation is “more stable.” The lesson is that stability evidence belongs to the product configuration that was actually tested.
This example describes FDA-approved products. It does not establish storage conditions or stability for a MitoCore product or for another semaglutide formulation.
View sources
Injectable Solution
Ozempic — aqueous injectable semaglutide
Oral Tablet
Rybelsus — oral semaglutide tablet
Same active molecule — different product configuration.
This example describes FDA-approved products. It does not establish storage conditions or stability for a MitoCore product or for another semaglutide formulation.
Educational content only. Stability depends on the exact molecule, formulation, presentation, manufacturing process, container, and evidence package. Product-specific regulatory or manufacturer labeling applies only to the product it describes. This module does not provide preparation, reconstitution, administration, dosing, or MitoCore product-storage instructions.
See where formulation fits in the peptide manufacturing journey→
Reading Stability Language Critically
When you see a stability claim, ask what evidence it actually describes.
What exact formulation was tested?
Was the material a solution, a dried solid, a tablet, or another presentation?
What concentration, excipients, and container system were used?
What quality attribute was measured?
Was the evidence from real-time stability, accelerated testing, or a stress study?
Is someone transferring data from one formulation to another without evidence that they behave the same way?
Those questions matter more than a generic statement that “the peptide is stable.”
Key Takeaways
- Stability is product-specific, not peptide-name-specific.
- Chemical and physical instability are different problems.
- Formulation and packaging can change stability behavior.
- Lyophilization can help some formulations, but it does not guarantee long-term stability.
- A COA is not a substitute for a stability study.
Sources
This educational module summarizes general pharmaceutical-science and regulatory principles. It does not publish product-specific MitoCore stability claims.
- ICH Q1A(R2)ICH Q1A(R2) — Stability Testing of New Drug Substances and Products, Step 4, 6 February 2003
- ICH Q5CFDA / ICH Q5C — Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, July 1996
- ICH Q1BFDA / ICH Q1B — Photostability Testing of New Drug Substances and Products, March 1996
- FDA — Ozempic labelFDA — Ozempic (semaglutide) prescribing information, revised 2025
- FDA — Rybelsus labelFDA — Rybelsus (semaglutide) prescribing information, revised 2025
- SOURCE 13Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review
- SOURCE 14Factors affecting the physical stability (aggregation) of peptide therapeutics
- Torosantucci et al. 2014Torosantucci R, Schöneich C, Jiskoot W — Oxidation of Therapeutic Proteins and Peptides
- Manning et al. 2017Manning MC et al. — Role of Buffers in Protein Formulations
- Roy & Gupta 2004Roy I, Gupta MN — Freeze-Drying of Proteins: Some Emerging Concerns
- Fekete et al. 2014Fekete S, Beck A, Veuthey JL, Guillarme D — Theory and Practice of Size Exclusion Chromatography for Protein Aggregate Analysis
